<?xml version="1.0" encoding="UTF-8"?>
<p>Based on the success of the ring vaccination strategy during the West Africa epidemic and Ã‰quateur outbreaks, the decision was made to use the same approach in Kivu. Vaccination using the rVSV-ZEBOV vaccine was begun on 8 August, and a ring vaccination program was implemented in an attempt to stop spread of transmission. In this program, the rVSV-ZEBOV vaccine was offered to contacts of known cases and the contacts of contacts, including any individual over 1 year of age. The DRC Ministry of Health, together with WHO and other partners, decided that pregnant and lactating women would, once again, be excluded from receiving rVSV-ZEBOV, the only Ebola vaccine to have completed efficacy testing. Thus, for the third sequential Ebola epidemic/outbreak, the rVSV-ZEBOV was administered to persons at risk but excluded pregnant and lactating women and infants [
 <xref rid="B1-vaccines-08-00038" ref-type="bibr">1</xref>,
 <xref rid="B11-vaccines-08-00038" ref-type="bibr">11</xref>,
 <xref rid="B15-vaccines-08-00038" ref-type="bibr">15</xref>].
</p>
